10X Genomics Inc vs Waste Management, Inc. — how do they compare? 10X Genomics Inc trades at $57.7 (market cap $7.61B), while Waste Management, Inc. trades at $226.84 (market cap $90.68B). The key difference: Waste Management, Inc. is far larger — about 11.9× 10X Genomics Inc's market cap, and Waste Management, Inc. pays a 1.56% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TXG | WM | |
|---|---|---|
Market Cap | $7.61B | $90.68B |
Sector | Health | Industrials |
52-Week High | $58.57 | $246.51 |
52-Week Low | $11.34 | $196.77 |
Enterprise Value | $7.14B | $113.47B |
Dividend Yield | — | 1.56% |
Signals from Pluang's Aura AI — not financial advice
TXG trades at $57.77, down 1.37% today, with a bullish technical outlook supported by moving averages and strong support at $55. The company shows improving fundamentals with Q2 2026 earnings beating estimates and positive cash flow trends, though it remains unprofitable with negative margins. Recent news highlights collaborations with major medical institutions and strategic acquisitions expanding multiomics capabilities.
Investment outlook is mixed: technical strength and analyst upgrades suggest near-term upside potential, but high valuation multiples and persistent losses pose significant risks. The stock faces pressure from competitive threats and execution challenges in achieving profitability, requiring careful monitoring of upcoming Q3 earnings and revenue growth sustainability.
WM trades at $226.19, down 0.18% today, with a neutral technical signal and strong fundamentals. Recent Q2 2026 earnings beat estimates at $2.02 per share, driven by pricing discipline and margin gains. Revenue growth is steady, with 2025 revenue at $25.20 billion, though net income margin dipped to 10.74%. The stock shows a bullish analyst consensus with a $263.43 price target, supported by 20 buy ratings and no sell recommendations. Institutional activity includes mixed trades, such as Bank of America reducing holdings by 6.1% in Q1 2026 (SEC filing, 2026-08-01).
Outlook remains positive due to consistent earnings beats and operational efficiency, but risks include high valuation ratios like a P/E of 59.74 and rising debt levels, with total liabilities at $36.31 billion in 2024. Investors should weigh growth potential against margin pressures and macroeconomic headwinds affecting waste volumes.
Trailing returns across standard periods
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →